{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:14:04Z","timestamp":1785402844311,"version":"3.56.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,30]]},"DOI":"10.7759\/cureus.113631","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:21:27Z","timestamp":1785399687000},"source":"Crossref","is-referenced-by-count":0,"title":["Optical Coherence Tomography Biomarkers in Diabetic Macular Edema and Their Role in Predicting Visual Outcome After Ranibizumab or Triamcinolone Injection"],"prefix":"10.7759","author":[{"given":"Shanmugasundaram","family":"Palanisamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadarshini","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagabat","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruttendu","family":"Moharana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijnya B","family":"Panda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sucheta","family":"Parija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathan Kumar","family":"Ramasubbu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan MA","year":"2020","unstructured":"Khan MA, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020, 10:107-11. 10.2991\/jegh.k.191028.001","journal-title":"J Epidemiol Glob Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2021.02.016","article-title":"Prevalence and trends of the diabetes epidemic in urban and rural India: a pooled systematic review and meta-analysis of 1.7 million adults","volume":"58","author":"Ranasinghe P","year":"2021","unstructured":"Ranasinghe P, Jayawardena R, Gamage N, Sivanandam N, Misra A. Prevalence and trends of the diabetes epidemic in urban and rural India: a pooled systematic review and meta-analysis of 1.7 million adults. Ann Epidemiol. 2021, 58:128-48. 10.1016\/j.annepidem.2021.02.016","journal-title":"Ann Epidemiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(03)12267-2","article-title":"Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study","volume":"361","author":"Younis N","year":"2003","unstructured":"Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet. 2003, 361:195-200. 10.1016\/s0140-6736(03)12267-2","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.02.002","article-title":"Prevalence and risk indicators of visual impairment and blindness in Latinos: the Los Angeles Latino Eye Study","volume":"111","author":"Varma R","year":"2004","unstructured":"Varma R, Ying-Lai M, Klein R, Azen SP. Prevalence and risk indicators of visual impairment and blindness in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004, 111:1132-40. 10.1016\/j.ophtha.2004.02.002","journal-title":"Ophthalmology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-11503","article-title":"Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients","volume":"54","author":"Kim JT","year":"2013","unstructured":"Kim JT, Lee DH, Joe SG, Kim JG, Yoon YH. Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients. Invest Ophthalmol Vis Sci. 2013, 54:3378-84. 10.1167\/iovs.12-11503","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000770","article-title":"Visual and morphologic outcomes of intravitreal ranibizumab for diabetic macular edema based on optical coherence tomography patterns","volume":"36","author":"Seo KH","year":"2016","unstructured":"Seo KH, Yu SY, Kim M, Kwak HW. Visual and morphologic outcomes of intravitreal ranibizumab for diabetic macular edema based on optical coherence tomography patterns. Retina. 2016, 36:588-95. 10.1097\/IAE.0000000000000770","journal-title":"Retina"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20855","article-title":"Functional and anatomical outcomes in patients with serous retinal detachment in diabetic macular edema treated with ranibizumab","volume":"58","author":"Giocanti-Aur\u00e9gan A","year":"2017","unstructured":"Giocanti-Aur\u00e9gan A, Hrarat L, Qu LM, et al.. Functional and anatomical outcomes in patients with serous retinal detachment in diabetic macular edema treated with ranibizumab. Invest Ophthalmol Vis Sci. 2017, 58:797-800. 10.1167\/iovs.16-20855","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.08.031","article-title":"OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant","volume":"125","author":"Zur D","year":"2018","unstructured":"Zur D, Iglicki M, Busch C, Invernizzi A, Mariussi M, Loewenstein A. OCT biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology. 2018, 125:267-75. 10.1016\/j.ophtha.2017.08.031","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-4493","article-title":"Optical coherence tomography may be used to predict visual acuity in patients with macular edema","volume":"52","author":"Pelosini L","year":"2011","unstructured":"Pelosini L, Hull CC, Boyce JF, McHugh D, Stanford MR, Marshall J. Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Invest Ophthalmol Vis Sci. 2011, 52:2741-8. 10.1167\/iovs.09-4493","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref10","article-title":"Repeatability and reproducibility of macular thickness measurements with the Humphrey OCT system","volume":"43","author":"Muscat S","year":"2002","unstructured":"Muscat S, Parks S, Kemp E, Keating D. Repeatability and reproducibility of macular thickness measurements with the Humphrey OCT system. Invest Ophthalmol Vis Sci. 2002, 43:490-5.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2174\/1874364100903010010","article-title":"Repeatability and reproducibility of macular thickness measurements using Fourier domain optical coherence tomography","volume":"3","author":"Bruce A","year":"2009","unstructured":"Bruce A, Pacey IE, Dharni P, Scally AJ, Barrett BT. Repeatability and reproducibility of macular thickness measurements using Fourier domain optical coherence tomography. Open Ophthalmol J. 2009, 3:10-4. 10.2174\/1874364100903010010","journal-title":"Open Ophthalmol J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12153","article-title":"Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment","volume":"91","author":"Reznicek L","year":"2013","unstructured":"Reznicek L, Cserhati S, Seidensticker F, et al.. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment. Acta Ophthalmol. 2013, 91:e529-36. 10.1111\/aos.12153","journal-title":"Acta Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22725","article-title":"Association between hyperreflective dots on spectral-domain optical coherence tomography in macular edema and response to treatment","volume":"58","author":"Hwang HS","year":"2017","unstructured":"Hwang HS, Chae JB, Kim JY, Kim DY. Association between hyperreflective dots on spectral-domain optical coherence tomography in macular edema and response to treatment. Invest Ophthalmol Vis Sci. 2017, 58:5958-67. 10.1167\/iovs.17-22725","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13935","article-title":"Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers","volume":"97","author":"Bonfiglio V","year":"2019","unstructured":"Bonfiglio V, Reibaldi M, Pizzo A, et al.. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers. Acta Ophthalmol. 2019, 97:e540-4. 10.1111\/aos.13935","journal-title":"Acta Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2021.1907423","article-title":"Optical coherence tomography biomarkers in bilateral diabetic macular edema patients with asymmetric anti-VEGF response","volume":"36","author":"Koc F","year":"2021","unstructured":"Koc F, G\u00fcven YZ, Egrilmez D, Ayd\u0131n E. Optical coherence tomography biomarkers in bilateral diabetic macular edema patients with asymmetric anti-VEGF response. Semin Ophthalmol. 2021, 36:444-51. 10.1080\/08820538.2021.1907423","journal-title":"Semin Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.09.002","article-title":"Long-term visual outcomes and morphologic biomarkers of vision loss in eyes with diabetic macular edema treated with anti-VEGF therapy","volume":"235","author":"Borrelli E","year":"2022","unstructured":"Borrelli E, Grosso D, Barresi C, et al.. Long-term visual outcomes and morphologic biomarkers of vision loss in eyes with diabetic macular edema treated with anti-VEGF therapy. Am J Ophthalmol. 2022, 235:80-9. 10.1016\/j.ajo.2021.09.002","journal-title":"Am J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.129122","article-title":"Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study)","volume":"92","author":"Paccola L","year":"2008","unstructured":"Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol. 2008, 92:76-80. 10.1136\/bjo.2007.129122","journal-title":"Br J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0493","article-title":"Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study","volume":"33","author":"Massin P","year":"2010","unstructured":"Massin P, Bandello F, Garweg JG, et al.. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010, 33:2399-405. 10.2337\/dc10-0493","journal-title":"Diabetes Care"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2017.6135","article-title":"Association of changes in macular perfusion with ranibizumab treatment for diabetic macular edema: a subanalysis of the RESTORE (Extension) Study","volume":"136","author":"Karst SG","year":"2018","unstructured":"Karst SG, Deak GG, Gerendas BS, et al.. Association of changes in macular perfusion with ranibizumab treatment for diabetic macular edema: a subanalysis of the RESTORE (Extension) Study. JAMA Ophthalmol. 2018, 136:315-21. 10.1001\/jamaophthalmol.2017.6135","journal-title":"JAMA Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1023\/b:inte.0000031744.93778.60","article-title":"Foveolar choroidal hemodynamics in proliferative diabetic retinopathy","volume":"25","author":"Schocket LS","year":"2004","unstructured":"Schocket LS, Brucker AJ, Niknam RM, Grunwald JE, DuPont J, Brucker AJ. Foveolar choroidal hemodynamics in proliferative diabetic retinopathy. Int Ophthalmol. 2004, 25:89-94. 10.1023\/b:inte.0000031744.93778.60","journal-title":"Int Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/511603-optical-coherence-tomography-biomarkers-in-diabetic-macular-edema-and-their-role-in-predicting-visual-outcome-after-ranibizumab-or-triamcinolone-injection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:21:28Z","timestamp":1785399688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/511603-optical-coherence-tomography-biomarkers-in-diabetic-macular-edema-and-their-role-in-predicting-visual-outcome-after-ranibizumab-or-triamcinolone-injection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.113631","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,30]]}}}